Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A Prospective double-blind randomised phase III clinical study

2023 · doi:10.1101/2022.12.29.22284049

preprint OA: closed

📄 Open PDF View at publisher

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

A Phase III Randomized Controlled Trial Assessing the Safety and Immunogenicity of Biological E’s XBB 1.5 RBD Subunit COVID-19 Booster Vaccine in Individuals Aged 5 to 80 Years 2025

Cited by (1)

A Phase III Randomized Controlled Trial Assessing the Safety and Immunogenicity of Biological E’s XBB 1.5 RBD Subunit COVID-19 Booster Vaccine in Individuals Aged 5 to 80 Years 2025

Source provenance

europepmc: last seen: 2026-05-19T01:45:01.086888+00:00